Intestinal Immunomodulation and Shifts on the Gut Microbiota of BALBc Mice Promoted by Two Bifidobacterium and Lactobacillus Strains Isolated from Human Samples

Abstract EN

Bifidobacterium animalis subsp.

lactis IPLA 20020 and Lactobacillus gasseri IPLA 20212, two strains isolated from human samples, were evaluated for safety and influence over the intestinal microbiota and cytokine production by the intestinal tissue of adult BALB/c mice.

Mice were divided into four groups receiving during 8 days PBS or a suspension of each strain, prepared fresh or lyophilized (bifidobacteria), at an amount of 4x108 viable cells/day.

This dose could be comparable to the probiotic intake of a human adult who consumed about 100-200 mL of functional fermented milk per day, considering the usual level of probiotics in commercial products.

No microbial translocation to liver or alterations in food intake, weight, and behavior were observed in treated mice.

Intestinal content of secretory immunoglobulin A (s-IgA) was not affected, discarding any adverse effect on the mucosa-associated immunity.

The profile of intestinal proinflammatory/regulatory cytokines after intervention evidenced that the microbial strain administered and its cellular state (fresh or lyophilized) as well as the host tissue analyzed (small or large intestine) influenced the immune response and suggests a moderate shift towards a T helper 1 profile (Th1) in the large intestine after the administration of both strains.

Changes on relative levels of some intestinal microbial groups were evidenced after intervention.

It is noteworthy that butyrate was positively associated with a balanced pro-Th1 immune response.

Therefore, B.

animalis subsp.

lactis IPLA20020 and L.

gasseri IPLA 20212 could be considered potential probiotic candidates to be included in functional foods for balancing the intestinal immune response.